newsfilter
← Latest News
GlobeNewswire·

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Leveraging Avalon's existing Flash-CARTM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeutics Clinical development of CAR-NK cell therapy planned in collaboration with the Company's clinical partner, Lu Daopei Hospital